Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Selection of PD1/PD-L1 X-Aptamers.

Literature DB >> 28912094

Selection of PD1/PD-L1 X-Aptamers.

Hongyu Wang¹, Curtis H Lam², Xin Li¹, Derek L West³, Xianbin Yang⁴.

Abstract

Specific, chemically modified aptamers (X-Aptamers) were identified against two immune checkpoint proteins, recombinant Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1). Selections were performed using a bead-based X-Aptamer (XA) library containing several different amino acid functional groups attached to dU at the 5-position. The binding affinities and specificities of the selected XA-PD1 and XA-PDL1 were validated by hPD-1 and hPD-L1 expression cells, as well as by binding to human pancreatic ductal adenocarcinoma tissue. The selected PD1 and PDL1 XAs can mimic antibody functions in in vitro assays.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28912094 PMCID： PMC5794648 DOI： 10.1016/j.biochi.2017.09.006

Source DB: PubMed Journal: Biochimie ISSN： 0300-9084 Impact factor: 4.079

36 in total

1. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing.

Authors: Xianbin Yang; Suzanne E Bassett; Xin Li; Bruce A Luxon; Norbert K Herzog; Robert E Shope; Judy Aronson; Tarl W Prow; James F Leary; Romy Kirby; Andrew D Ellington; David G Gorenstein
Journal: Nucleic Acids Res Date: 2002-12-01 Impact factor: 16.971

2. Strategies for the discovery of therapeutic aptamers.

Authors: Xianbin Yang; Na Li; David G Gorenstein
Journal: Expert Opin Drug Discov Date: 2011-01 Impact factor: 6.098

3. In vivo IL-4 prevents allo-antigen driven CD8⁺ CTL development.

Authors: Charles S Via; Kateryna Soloviova; Maksym Puliaiev; Roman Puliav; Irina Puliaeva; Suzanne C Morris; Fred D Finkelman
Journal: Clin Immunol Date: 2017-03-27 Impact factor: 3.969

4. Determining Functional Aptamer-Protein Interaction by Biolayer Interferometry.

Authors: Xinhui Lou; Martin Egli; Xianbin Yang
Journal: Curr Protoc Nucleic Acid Chem Date: 2016-12-01

Review 5. Mechanisms of Resistance to Immune Checkpoint Antibodies.

Authors: Rodrigo N Ramos; Eliane Piaggio; Emanuela Romano
Journal: Handb Exp Pharmacol Date: 2018

6. Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

Authors: Yongxun Zhuansun; Fengting Huang; Yumo Du; Lin Lin; Rui Chen; Jianguo Li
Journal: J Thorac Dis Date: 2017-03 Impact factor: 2.895

7. Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections.

Authors: Susan M Fennewald; Erin P Scott; Lihong Zhang; Xianbin Yang; Judith F Aronson; David G Gorenstein; Bruce A Luxon; Robert E Shope; David W C Beasley; Alan D T Barrett; Norbert K Herzog
Journal: J Gen Virol Date: 2007-03 Impact factor: 3.891

Review 8. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.

Authors: John C Rohloff; Amy D Gelinas; Thale C Jarvis; Urs A Ochsner; Daniel J Schneider; Larry Gold; Nebojsa Janjic
Journal: Mol Ther Nucleic Acids Date: 2014-10-07 Impact factor: 10.183

9. Computational design of the affinity and specificity of a therapeutic T cell receptor.

Authors: Brian G Pierce; Lance M Hellman; Moushumi Hossain; Nishant K Singh; Craig W Vander Kooi; Zhiping Weng; Brian M Baker
Journal: PLoS Comput Biol Date: 2014-02-13 Impact factor: 4.475

10. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.

Authors: Nina Deppisch; Peter Ruf; Nina Eißler; Horst Lindhofer; Ralph Mocikat
Journal: Oncotarget Date: 2017-01-17

9 in total

Review 1. Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors: S K Haßel; G Mayer
Journal: Mol Diagn Ther Date: 2019-06 Impact factor: 4.074

2. Crystal structures of thrombin in complex with chemically modified thrombin DNA aptamers reveal the origins of enhanced affinity.

Authors: Rafal Dolot; Curtis H Lam; Malgorzata Sierant; Qiang Zhao; Feng-Wu Liu; Barbara Nawrot; Martin Egli; Xianbin Yang
Journal: Nucleic Acids Res Date: 2018-05-18 Impact factor: 16.971

Selection of PD1/PD-L1 X-Aptamers.

1. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing.

2. Strategies for the discovery of therapeutic aptamers.

3. In vivo IL-4 prevents allo-antigen driven CD8⁺ CTL development.

4. Determining Functional Aptamer-Protein Interaction by Biolayer Interferometry.

Review 5. Mechanisms of Resistance to Immune Checkpoint Antibodies.

6. Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

7. Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections.

Review 8. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.

9. Computational design of the affinity and specificity of a therapeutic T cell receptor.

10. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.

Review 1. Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

2. Crystal structures of thrombin in complex with chemically modified thrombin DNA aptamers reveal the origins of enhanced affinity.

Review 3. Diagnostic and Therapeutic Value of Aptamers in Envenomation Cases.

Review 4. The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research.

Review 5. Cancer immunomodulation using bispecific aptamers.

6. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.

7. High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.

Review 8. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.

9. Synthesis and characterization of novel ssDNA X-aptamers targeting Growth Hormone Releasing Hormone (GHRH).